Mycobacterium fortuitum

Mycobacterium fortuitum
A scanning electron micrograph of Mycobacterium fortuitum
Scientific classification edit
Domain: Bacteria
Phylum: Actinomycetota
Class: Actinomycetia
Order: Mycobacteriales
Family: Mycobacteriaceae
Genus: Mycobacterium
Species:
M. fortuitum
Binomial name
Mycobacterium fortuitum
Da Costa Cruz 1938, ATCC 6841

Mycobacterium fortuitum is a nontuberculous species of the phylum Actinomycetota (Gram-positive bacteria with high guanine and cytosine content, one of the dominant phyla of all bacteria), belonging to the genus Mycobacterium.

Description

Gram-positive, nonmotile and acid-fast rods (1-3 µm x 0.2-0.4 µm). Sometimes long rods with occasional beaded or swollen cells having non-acid-fast ovoid bodies at one end.

Colony characteristics

  • Smooth hemispheric colonies, usually off-white or cream colored. May be butyrous, waxy, multilobate and even rosette clustered (dilute inocula).
  • On Malachite green containing media, such as Löwenstein-Jensen media, colonies can absorb the green dye.

Physiology

  • Rapid growth on Löwenstein-Jensen media within 2–4 days.
  • No growth at 45 °C, but grows on MacConkey agar.

Differential characteristics

  • Differentiation from M. fortuitum subsp. acetamidolyticum by its ability to use L-glutamate and its inability to use acetamide as simultaneous nitrogen and carbon source. Both subspecies share an identical 5'-16S rDNA sequence. However, the ITS sequences are different.

Type strain

  • Found world-wide in soil, dust, rivers, lakes and tap water.
  • First isolated from a 25-year-old patient (syringe abscess) in Rio de Janeiro.
  • Also isolated from lymph glands of cattle and systemic or nodular infection of frogs.

Strain ATCC 6841 = CCUG 20994 = CIP 104534 = DSM 46621 = IFO (now NBRC) 13159 = JCM 6387 = NCTC 10394.

Subsequently, this species has been divided into subspecies M. fortuitum subsp. acetamidolyticum

Background

Mycobacterium fortuitum is a fast-growing species that can cause infections. The term "fast growing" is a reference to a growth rate of 3 or 4 days, when compared to other Mycobacteria that may take weeks to grow out on laboratory media. Pulmonary infections of M. fortuitum are uncommon, but Mycobacterium fortuitum can cause local skin disease, osteomyelitis (inflammation of the bone), joint infections and infections of the eye after trauma. Mycobacterium fortuitum has a worldwide distribution and can be found in natural and processed water, sewage, and dirt.

Bacteria classified as Mycobacteria, include the causative agents for tuberculosis and leprosy. Mycobacteria are sometimes referred to as “acid-fast bacteria,” a term referencing their response to a laboratory staining technique. This simply means that when microscopic slides of these bacteria are rinsed with an acidic solution, they retain a red dye. Mycobacterium fortuitum is one of the many species of nontuberculosis mycobacteria (NTM) that are commonly found in the environment. These are not involved in tuberculosis. This does not mean, however, that they will not cause an infection in the right circumstances.

M. fortuitum infection can be a nosocomial (hospital acquired) disease. Surgical sites may become infected after the wound is exposed directly or indirectly to contaminated tap water. Other possible sources of M. fortuitum infection include implanted devices such as catheters, injection site abscesses, and contaminated endoscopes. Recent publication on Rapidly Growing Mycobacteria (RGM) is available provides the following aspects of RGM: (i) its sources, predisposing factors, clinical manifestations, and concomitant fungal infections; (ii) the risks of misdiagnoses in the management of RGM infections in dermatological settings; (iii) the diagnoses and outcomes of treatment responses in common and uncommon infections in immunocompromised and immunocompetent patients; (iv) conventional versus current molecular methods for the detection of RGM; (v) the basic principles of a promising MALDI-TOF MS, sampling protocol for cutaneous or subcutaneous lesions and its potential for the precise differentiation of M. fortuitum, M. chelonae, and M. abscessus; and (vi) improvements in RGM infection management as described in the recent 2011 Clinical and Laboratory Standards Institute (CLSI) guidelines, including interpretation criteria of molecular methods and antimicrobial drug panels and their break points [minimum inhibitory concentrations (MICs)], which have been highlighted for the initiation of antimicrobial therapy (Kothavade RJ et al., 2012).

Infection

Dermal piercing site at time of infection Mycobacterium fortuitum

Treatment

The 2007 guideline “Official American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) statement: diagnosis, treatment, and prevention of non-tuberculosis mycobacterial diseases”, notes that M. fortuitum isolates are usually susceptible to multiple oral antimicrobial agents, including the macrolides, quinolones, some tetracyclines, and sulfonamides, as well as the intravenous carbapenems (e.g. imipenem). Ondansetron HCL (Zofran) is an antiemetic often given to offset the nausea and vomiting that are a common side effect of Imipenem. Severe infections require IV treatment combined with oral antibiotics for a prolonged period, up to several months. The guideline recommends “for serious skin, bone, and soft tissue M fortuitum disease, a minimum of 4 months of therapy with at least two agents with in vitro activity against the clinical isolate is necessary to provide a high likelihood of cure. Surgery is generally indicated with extensive disease, abscess formation, or where drug therapy is difficult.”

References

  1. ↑ Mycobacterium Fortuitum at eMedicine

Further reading

  • National Institutes of Health, Office of Rare Disease Research, Genetic and Rare Diseases Information Center (GARD) http://rarediseases.info.nih.gov/GARD/Condition/9773/Mycobacterium_fortuitum.aspx Archived 2013-01-27 at the Wayback Machine
  • Da Costa Cruz, J. 1938. Mycobacterium fortuitum um novo bacillo acido-resistente patogênico para o homem. Acta Medica (Rio de Janeiro), 1, 297-301.]
  • Kothavade, RJ; Dhurat, RS; Mishra, SN; Kothavade, UR (2013). "Clinical and laboratory aspects of the diagnosis and management of cutaneous and subcutaneous infections caused by rapidly growing mycobacteria". European Journal of Clinical Microbiology & Infectious Diseases. 32 (2): 161–88. doi:10.1007/s10096-012-1766-8. PMID 23139042. S2CID 207052079.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.